An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway

• James Lu ,

  * E-mail: james.lu.jl1@roche.com

  Affiliation F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Clinical Pharmacology, Basel, Switzerland

  ⨯
• Katrin Hübner,

  Affiliation BioQuant, University of Heidelberg, Heidelberg, Germany

  ⨯
• M. Nazeem Nanjee,

  Affiliation Division of Cardiovascular Genetics, University of Utah, Salt Lake City, Utah, United States of America

  ⨯
• Eliot A. Brinton,

  Affiliation Utah Foundation for Biomedical Research, Salt Lake City, Utah, United States of America

  ⨯
• Norman A. Mazer

  Affiliation F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Clinical Pharmacology, Basel, Switzerland

  ⨯